MoonLake Immunotherapeutics (MLTX) Stock Forecast, Price Target & Predictions
MLTX Stock Forecast
MoonLake Immunotherapeutics stock forecast is as follows: an average price target of $79.33 (represents a 70.97% upside from MLTX’s last price of $46.40) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
MLTX Price Target
The average price target for MoonLake Immunotherapeutics (MLTX) is $79.33 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $100.00 to $62.00. This represents a potential 70.97% upside from MLTX's last price of $46.40.
MLTX Analyst Ratings
According to 7 Wall Street analysts, MoonLake Immunotherapeutics's rating consensus is 'Buy'. The analyst rating breakdown for MLTX stock is 0 'Strong Buy' (0.00%), 6 'Buy' (85.71%), 1 'Hold' (14.29%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
MoonLake Immunotherapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 01, 2024 | Raghuram Selvaraju | H.C. Wainwright | $100.00 | $43.97 | 127.43% | 115.52% |
| Apr 02, 2024 | Richard Law | Goldman Sachs | $62.00 | $48.60 | 27.57% | 33.62% |
| Aug 31, 2023 | Serge Belanger | Needham | $76.00 | $56.09 | 35.48% | 63.79% |
The latest MoonLake Immunotherapeutics stock forecast, released on Jul 01, 2024 by Raghuram Selvaraju from H.C. Wainwright, set a price target of $100.00, which represents a 127.43% increase from the stock price at the time of the forecast ($43.97), and a 115.52% increase from MLTX last price ($46.40).
MoonLake Immunotherapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 2 |
| Avg Price Target | - | - | $81.00 |
| Last Closing Price | $46.40 | $46.40 | $46.40 |
| Upside/Downside | -100.00% | -100.00% | 74.57% |
In the current month, the average price target of MoonLake Immunotherapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to MoonLake Immunotherapeutics's last price of $46.40. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 15, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 12, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Sep 12, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 26, 2024 | Wolfe Research | - | Peer Perform | Downgrade |
| Jul 01, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 24, 2024 | Oppenheimer | - | Outperform | Initialise |
| Apr 02, 2024 | Goldman Sachs | - | Neutral | Initialise |
| Aug 31, 2023 | Needham | - | Buy | Initialise |
| Feb 14, 2023 | Cantor Fitzgerald | - | Overweight | Initialise |
| Nov 11, 2022 | Jefferies | - | Buy | Initialise |
MoonLake Immunotherapeutics's last stock rating was published by H.C. Wainwright on Oct 15, 2024. The company gave MLTX a "Buy" rating, the same as its previous rate.
MoonLake Immunotherapeutics Financial Forecast
MoonLake Immunotherapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
MoonLake Immunotherapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. MLTX's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
MoonLake Immunotherapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict MLTX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than MoonLake Immunotherapeutics's previous annual EBITDA (undefined) of $NaN.
MoonLake Immunotherapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-41.18M | $-41.81M | $-42.55M | $-37.93M | $-31.32M | $-27.76M | $-17.41M |
| High Forecast | $-41.18M | $-41.81M | $-42.55M | $-37.93M | $-31.32M | $-20.36M | $-17.41M |
| Low Forecast | $-41.18M | $-41.81M | $-42.55M | $-37.93M | $-31.32M | $-32.70M | $-17.41M |
| Surprise % | - | - | - | - | - | - | - |
MoonLake Immunotherapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. MLTX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
MoonLake Immunotherapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
MoonLake Immunotherapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to MLTX last annual SG&A of $NaN (undefined).
MoonLake Immunotherapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.66 | $-0.67 | $-0.68 | $-0.60 | $-0.50 | $-0.44 | $-0.28 |
| High Forecast | $-0.66 | $-0.67 | $-0.68 | $-0.60 | $-0.50 | $-0.32 | $-0.28 |
| Low Forecast | $-0.66 | $-0.67 | $-0.68 | $-0.60 | $-0.50 | $-0.52 | $-0.28 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, MoonLake Immunotherapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to MLTX previous annual EPS of $NaN (undefined).
MoonLake Immunotherapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VTYX | Ventyx Biosciences | $2.15 | $33.86 | 1474.88% | Buy |
| AVTE | Aerovate Therapeutics | $2.72 | $13.00 | 377.94% | Hold |
| CMPX | Compass Therapeutics | $1.70 | $5.00 | 194.12% | Buy |
| PLRX | Pliant Therapeutics | $14.49 | $39.71 | 174.05% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.81 | $38.80 | 161.99% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.95 | $7.00 | 137.29% | Buy |
| ETNB | 89bio | $9.29 | $22.00 | 136.81% | Buy |
| GPCR | Structure Therapeutics | $39.74 | $92.40 | 132.51% | Buy |
| TERN | Terns Pharmaceuticals | $7.10 | $14.25 | 100.70% | Buy |
| MLTX | MoonLake Immunotherapeutics | $46.40 | $79.33 | 70.97% | Buy |
| AKRO | Akero Therapeutics | $32.05 | $46.00 | 43.53% | Buy |
| ELVN | Enliven Therapeutics | $27.65 | $35.50 | 28.39% | Buy |
| NUVL | Nuvalent | $89.53 | $107.83 | 20.44% | Buy |
| TVTX | Travere Therapeutics | $18.10 | $21.38 | 18.12% | Buy |
| AMLX | Amylyx Pharmaceuticals | $5.70 | $5.33 | -6.49% | Buy |
| ACLX | Arcellx | $86.44 | $71.57 | -17.20% | Buy |
| CERE | Cerevel Therapeutics | $44.96 | $33.50 | -25.49% | Buy |
MLTX Forecast FAQ
Is MoonLake Immunotherapeutics a good buy?
Yes, according to 7 Wall Street analysts, MoonLake Immunotherapeutics (MLTX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 85.71% of MLTX's total ratings.
What is MLTX's price target?
MoonLake Immunotherapeutics (MLTX) average price target is $79.33 with a range of $62 to $100, implying a 70.97% from its last price of $46.4. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will MoonLake Immunotherapeutics stock go up soon?
According to Wall Street analysts' prediction for MLTX stock, the company can go up by 70.97% (from the last price of $46.4 to the average price target of $79.33), up by 115.52% based on the highest stock price target, and up by 33.62% based on the lowest stock price target.
Can MoonLake Immunotherapeutics stock reach $70?
MLTX's average twelve months analyst stock price target of $79.33 supports the claim that MoonLake Immunotherapeutics can reach $70 in the near future.
What are MoonLake Immunotherapeutics's analysts' financial forecasts?
MoonLake Immunotherapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-76.5M (high $-69.097M, low $-81.436M), average SG&A $0 (high $0, low $0), and average EPS is $-1.217 (high $-1.099, low $-1.295). MLTX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-163M (high $-163M, low $-163M), average SG&A $0 (high $0, low $0), and average EPS is $-2.6 (high $-2.6, low $-2.6).